The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial.
Liana K BillingsBue F Ross AgnerYuksel AltuntasRandi GrønNatalie HalladinDavid C KlonoffNikolaos TentolourisEsteban JódarPublished in: Journal of diabetes science and technology (2020)
NCT02420262.